Current developments in the design of onco-retrovirus and lentivirus vector systems for hematopoietic cell gene therapy.
Over the past dozen years, the majority of clinical gene therapy trials for inherited genetic diseases and cancer therapy have been performed using murine onco-retrovirus as the gene delivery vector. The earliest systems used were relatively inefficient in both the rates of transduction and expression of the transgene. Formidable obstacles inherent in the cell biology and/or the immunology of the target cell systems limited the efficacy of gene therapy for many target diseases. Development of novel retrovirus gene transfer systems that are in progress have begun to overcome these obstacles. Evidence of this progress is the recent successful functional correction of the immune T and B lymphocyte deficiency in patients with X-linked severe combined immunodeficiency (X-SCID) and adenosine deaminase (ADA)-deficient SCID following onco-retrovirus vector ex vivo transduction of autologous marrow stem cells [Science 296 (2002) 2410; Science 288 (2000) 669; N. Engl. J. Med. 346 (2002) 1185]. These achievements of prolonged clinical benefit from gene therapy were tempered by the finding of insertional mutageneses in two of the treated X-SCID patients [N. Engl. J. Med. 348 (2003) 255].
Brenner
Sebastian
S
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. sbrenner@nih.gov
Malech
Harry L
HL
D000818:Animals; D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000627:therapeutic use; D006412:Hematopoietic Stem Cells; D006801:Humans; D016086:Lentivirus; D012190:Retroviridae; D016092:Spumavirus; D014161:Transduction, Genetic